Compounds > 6-aminodopamine
Page last updated: 2024-11-08

6-aminodopamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

6-aminodopamine: cytotoxic agent; RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID170045
CHEMBL ID131384
SCHEMBL ID2320444
MeSH IDM0049144

Synonyms (8)

Synonym
4-amino-5-(2-amino-ethyl)-benzene-1,2-diol
bdbm50031344
6-aminodopamine
CHEMBL131384 ,
38411-80-2
1,2-benzenediol, 4-amino-5-(2-aminoethyl)-
SCHEMBL2320444
DTXSID50191750
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Sodium-dependent dopamine transporterRattus norvegicus (Norway rat)Ki0.01700.00030.37088.1600AID65474
TransporterRattus norvegicus (Norway rat)Ki0.01100.00010.866710.0000AID145874
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (29)

Assay IDTitleYearJournalArticle
AID139666Long term depletion of Norepinephrine (NE) in Whole mouse Brain at a high dose (300 nmol)1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
In vivo and in vitro studies on the neurotoxic potential of 6-hydroxydopamine analogs.
AID65474Evaluated for the Competitive inhibition of uptake of dopamine transporter1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
In vivo and in vitro studies on the neurotoxic potential of 6-hydroxydopamine analogs.
AID139654Long term depletion of Dopamine(DA) in Whole mouse Brain at a low dose (60 nmol)1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
In vivo and in vitro studies on the neurotoxic potential of 6-hydroxydopamine analogs.
AID1144321Inhibition of Sprague-Dawley rat liver COMT using 10 mM DHA/0.4 mM SAH as substrate assessed as residual activity under aerobic condition at 189 uM at 37 degC after 40 mins relative to control1976Journal of medicinal chemistry, Jan, Volume: 19, Issue:1
Catechol O-methyltransferase. 7. Affinity labeling with the oxidation products of 6-aminodopamine.
AID1144312Inhibition of Sprague-Dawley rat liver COMT assessed as residual activity under anaerobic condition at 189 uM at 37 degC after 40 mins relative to control1976Journal of medicinal chemistry, Jan, Volume: 19, Issue:1
Catechol O-methyltransferase. 7. Affinity labeling with the oxidation products of 6-aminodopamine.
AID1144314Inhibition of Sprague-Dawley rat liver COMT assessed as residual activity under aerobic condition at 189 uM at 37 degC after 40 mins in presence of catalase relative to control1976Journal of medicinal chemistry, Jan, Volume: 19, Issue:1
Catechol O-methyltransferase. 7. Affinity labeling with the oxidation products of 6-aminodopamine.
AID175698Evaluated for the stimulation of synaptosomal release of norepinephrine (release constant)1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
In vivo and in vitro studies on the neurotoxic potential of 6-hydroxydopamine analogs.
AID1144333Inhibition of Sprague-Dawley rat liver COMT using > 0.3 mM SAH as substrate at 0.19 mM at 37 degC after 40 mins1976Journal of medicinal chemistry, Jan, Volume: 19, Issue:1
Catechol O-methyltransferase. 7. Affinity labeling with the oxidation products of 6-aminodopamine.
AID1144320Inhibition of Sprague-Dawley rat liver COMT using 10 mM DHA/0.4 mM SAM as substrate assessed as residual activity under aerobic condition at 189 uM at 37 degC after 40 mins relative to control1976Journal of medicinal chemistry, Jan, Volume: 19, Issue:1
Catechol O-methyltransferase. 7. Affinity labeling with the oxidation products of 6-aminodopamine.
AID139816Long term depletion of Serotonin(5-HT) in Whole mouse Brain at a low dose (60 nmol)1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
In vivo and in vitro studies on the neurotoxic potential of 6-hydroxydopamine analogs.
AID1144332Inhibition of Sprague-Dawley rat liver COMT using > 0.3 mM SAM as substrate at 0.19 mM at 37 degC after 40 mins1976Journal of medicinal chemistry, Jan, Volume: 19, Issue:1
Catechol O-methyltransferase. 7. Affinity labeling with the oxidation products of 6-aminodopamine.
AID1144313Inhibition of Sprague-Dawley rat liver COMT assessed as residual activity under aerobic condition at 189 uM at 37 degC after 40 mins in presence of antioxidant sodium metabisulfite relative to control1976Journal of medicinal chemistry, Jan, Volume: 19, Issue:1
Catechol O-methyltransferase. 7. Affinity labeling with the oxidation products of 6-aminodopamine.
AID1144319Inhibition of Sprague-Dawley rat liver COMT using 2.5 mM DHA/0.4 mM SAM as substrate assessed as residual activity under aerobic condition at 189 uM at 37 degC after 40 mins relative to control1976Journal of medicinal chemistry, Jan, Volume: 19, Issue:1
Catechol O-methyltransferase. 7. Affinity labeling with the oxidation products of 6-aminodopamine.
AID1144261Depletion of norepinephrine in mouse brain at 50 ug administered intracranially at 24 hrs interval on three successive days measured 24 hrs post last dose relative to control1976Journal of medicinal chemistry, Jan, Volume: 19, Issue:1
Synthesis and evaluation of brain catecholamine depletion by N-alkyl derivatives of 6-aminodopamine.
AID145874Evaluated for the Competitive inhibition of uptake of norepinephrine1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
In vivo and in vitro studies on the neurotoxic potential of 6-hydroxydopamine analogs.
AID1144311Inhibition of Sprague-Dawley rat liver COMT assessed as residual activity under aerobic condition at 189 uM at 37 degC after 40 mins relative to control1976Journal of medicinal chemistry, Jan, Volume: 19, Issue:1
Catechol O-methyltransferase. 7. Affinity labeling with the oxidation products of 6-aminodopamine.
AID1144262Depletion of dopamine in mouse brain at 50 ug administered intracranially at 24 hrs interval on three successive days measured 24 hrs post last dose relative to control1976Journal of medicinal chemistry, Jan, Volume: 19, Issue:1
Synthesis and evaluation of brain catecholamine depletion by N-alkyl derivatives of 6-aminodopamine.
AID27360Compound was tested for neurotoxic property after intracranial administration in mice1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Oxidation of 5-hydroxytryptamine and 5,7-dihydroxytryptamine. A new oxidation pathway and formation of a novel neurotoxin.
AID1144331Chemical stability of the compound in seal ampules containing water under nitrogenous condition at 5 umol/ml measured up to 4 hrs1976Journal of medicinal chemistry, Jan, Volume: 19, Issue:1
Catechol O-methyltransferase. 7. Affinity labeling with the oxidation products of 6-aminodopamine.
AID1144318Inhibition of Sprague-Dawley rat liver COMT using 0.76 mM SAH as substrate assessed as residual activity under aerobic condition at 189 uM at 37 degC after 40 mins relative to control1976Journal of medicinal chemistry, Jan, Volume: 19, Issue:1
Catechol O-methyltransferase. 7. Affinity labeling with the oxidation products of 6-aminodopamine.
AID1144330Inhibition of Sprague-Dawley rat liver COMT at 0.25 mM preincubated for > 50 mins at 37 degC1976Journal of medicinal chemistry, Jan, Volume: 19, Issue:1
Catechol O-methyltransferase. 7. Affinity labeling with the oxidation products of 6-aminodopamine.
AID1144315Inhibition of Sprague-Dawley rat liver COMT using 2.5 mM DHA as substrate assessed as residual activity under aerobic condition at 189 uM at 37 degC after 40 mins relative to control1976Journal of medicinal chemistry, Jan, Volume: 19, Issue:1
Catechol O-methyltransferase. 7. Affinity labeling with the oxidation products of 6-aminodopamine.
AID1144317Inhibition of Sprague-Dawley rat liver COMT using 0.76 mM SAM as substrate assessed as residual activity under aerobic condition at 189 uM at 37 degC after 40 mins relative to control1976Journal of medicinal chemistry, Jan, Volume: 19, Issue:1
Catechol O-methyltransferase. 7. Affinity labeling with the oxidation products of 6-aminodopamine.
AID139653Long term depletion of Dopamine(DA) in Whole mouse Brain at a high dose (300 nmol)1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
In vivo and in vitro studies on the neurotoxic potential of 6-hydroxydopamine analogs.
AID175697Evaluated for the stimulation of synaptosomal release of Dopamine (release constant)1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
In vivo and in vitro studies on the neurotoxic potential of 6-hydroxydopamine analogs.
AID1144316Inhibition of Sprague-Dawley rat liver COMT using 10 mM DHA as substrate assessed as residual activity under aerobic condition at 189 uM at 37 degC after 40 mins relative to control1976Journal of medicinal chemistry, Jan, Volume: 19, Issue:1
Catechol O-methyltransferase. 7. Affinity labeling with the oxidation products of 6-aminodopamine.
AID139815Long term depletion of Serotonin(5-HT) in Whole mouse Brain at a high dose (300 nmol)1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
In vivo and in vitro studies on the neurotoxic potential of 6-hydroxydopamine analogs.
AID139667Long term depletion of Norepinephrine (NE) in Whole mouse Brain at a low dose (60 nmol)1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
In vivo and in vitro studies on the neurotoxic potential of 6-hydroxydopamine analogs.
AID1144335Irreversible inhibition of Sprague-Dawley rat liver COMT1976Journal of medicinal chemistry, Jan, Volume: 19, Issue:1
Catechol O-methyltransferase. 7. Affinity labeling with the oxidation products of 6-aminodopamine.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19908 (80.00)18.7374
1990's1 (10.00)18.2507
2000's1 (10.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.77

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.77 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.17 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.77)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
4-aminophenol
4-aminophenol: RN given refers to parent cpd. 4-aminophenol : An amino phenol (one of the three possible isomers) which has the single amino substituent located para to the phenolic -OH group.		7.0210aminophenolallergen;
metabolite
urea
pseudourea: clinical use; structure. isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.		2.0210isourea;
monocarboxylic acid amide;
one-carbon compound		Daphnia magna metabolite;
Escherichia coli metabolite;
fertilizer;
flour treatment agent;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine: A dopaminergic neurotoxic compound which produces irreversible clinical, chemical, and pathological alterations that mimic those found in Parkinson disease.. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine : A tetrahydropyridine that is 1,2,3,6-tetrahydropyridine substituted by a methyl group at position 1 and a phenyl group at position 4.		1.9710methylpyridines;
phenylpyridine;
tetrahydropyridine		neurotoxin
hydroxyindoleacetic acid
(5-hydroxyindol-3-yl)acetic acid : A member of the class of indole-3-acetic acids that is indole-3-acetic acid substituted by a hydroxy group at C-5.		1.9610indole-3-acetic acidsdrug metabolite;
human metabolite;
mouse metabolite
oxidopamine
Oxidopamine: A neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in the brain. Its mechanism of action is related to the production of cytolytic free-radicals.. oxidopamine : A benzenetriol that is phenethylamine in which the hydrogens at positions 2, 4, and 5 on the phenyl ring are replaced by hydroxy groups. It occurs naturally in human urine, but is also produced as a metabolite of the drug DOPA (used for the treatment of Parkinson's disease).		3.0650benzenetriol;
catecholamine;
primary amino compound		drug metabolite;
human metabolite;
neurotoxin
5,7-dihydroxytryptamine
5,7-Dihydroxytryptamine: Tryptamine substituted with two hydroxyl groups in positions 5 and 7. It is a neurotoxic serotonin analog that destroys serotonergic neurons preferentially and is used in neuropharmacology as a tool.		1.9610
2,4,5-trihydroxyamphetamine
2,4,5-trihydroxyamphetamine: structure given in first source; an in vitro metabolite of 2-hydroxy-4,5-(methylenedioxy)amphetamine		1.9810
5-amino-2,4-dihydroxy-alpha-methylphenylethylamine
[no description available]		1.9810
hydroxyl radical
Hydroxyl Radical: The univalent radical OH. Hydroxyl radical is a potent oxidizing agent.		1.9710oxygen hydride;
oxygen radical;
reactive oxygen species
ascorbic acid
Ascorbic Acid: A six carbon compound related to glucose. It is found naturally in citrus fruits and many vegetables. Ascorbic acid is an essential nutrient in human diets, and necessary to maintain connective tissue and bone. Its biologically active form, vitamin C, functions as a reducing agent and coenzyme in several metabolic pathways. Vitamin C is considered an antioxidant.. L-ascorbic acid : The L-enantiomer of ascorbic acid and conjugate acid of L-ascorbate.. L-ascorbate : The L-enantiomer of ascorbate and conjugate base of L-ascorbic acid, arising from selective deprotonation of the 3-hydroxy group. Required for a range of essential metabolic reactions in all animals and plants.. vitamin C : Any member of a group of vitamers that belong to the chemical structural class called butenolides that exhibit biological activity against vitamin C deficiency in animals. The vitamers include L-ascorbic acid and its salt, ionized and oxidized forms.		1.9610ascorbic acid;
vitamin C		coenzyme;
cofactor;
flour treatment agent;
food antioxidant;
food colour retention agent;
geroprotector;
plant metabolite;
skin lightening agent
ConditionIndicatedRelationship StrengthStudiesTrials
Malignant Melanoma
[description not available]		02.0210
Melanoma
A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)		02.0210
Idiopathic Parkinson Disease
[description not available]		02.3720
Parkinson Disease
A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)		02.3720
Atherosclerotic Parkinsonism
[description not available]		01.9710
Parkinson Disease, Secondary
Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)		01.9710